Clin Osteol 2021; 26(4): 186-190

Osteoporosis care during the COVID-19 pandemicReview articles

Rosa Jan
Osteocentrum Affidea Praha, s. r. o.

COVID-19 is an emerging infectious disease that has specific characteristics that interfere with the care of patients with osteoporosis. This article discusses the interfaces between osteological issues and COVID-19. A prevalent fracture very modestly increases the risk of death from COVID-19 but in hospitalized patients, the prevalence of vertebral fracture can be considered another aspect of polymorbidity increasing the likelihood of an adverse course of infection. Vitamin D deficiency correlates with worse outcomes in COVID-19, and sufficient vitamin D saturation is very likely protective in relation to COVID-19. Containment measures at the peak of the pandemic may result in muscle loss and increased risk of falls in the elderly. Densitometry and majority of laboratory tests can be easily delayed in patients with osteoporosis. This also applies to parenteral administration of bisphosphonates, whereas continuation of oral bisphosphonate therapy can be ensured by electronic prescription. Teriparatide should not be discontinued for more than 2-3 months, and the interval between denosumab administrations should not exceed 7 months.

Keywords: bisphosphonates; denosumab; fractures; COVID-19; osteoporosis

Received: October 12, 2021; Accepted: December 11, 2021; Published: December 11, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jan R. Osteoporosis care during the COVID-19 pandemic. Clinical Osteology. 2021;26(4):186-190.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Berlin DA, Gulick RM, Martinez FJ. Severe COVID-19. NEJM 2020; 383(25): 2451-2460. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMcp2009575A>. Go to original source...
    2. Cantini F, Goletti D, Petrone L. Immune therapy, or antiviral therapy, or both for COVID-19: a systematic review. Drugs 2020; 80(18): 1929-1946. Dostupné z DOI: <https://doi.org/10.1007/s40265-020-01421-w>. Go to original source...
    3. Formenti AM, Pedone E, di Filippo L et al. Are women with osteoporosis treated with denosumab at risk of severe COVID-19? Endocrine 2020; 70(2): 203-205. Dostupné z DOI: <hhtp://dx.doi.org/10.1007/s12020-020-02500-4>. Go to original source...
    4. Cleverley J, Piper J, Jones MM. The role of chest radiography in confirming COVID -19 pneumonia. BMJ 2020; 370:m2426. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.m2426> Go to original source...
    5. WHO Coronavirus (COVID-19) Dashboard. Dostupné z WWW: <https://covid19.who.int/>.
    6. Český statistický úřad. Počet zemřelých (aktualizace týdenních časových řad) -⁠ časové řady. Dostupné z WWW: <https://www.czso.cz/csu/czso/obypz_cr>.
    7. Yoneda T, Mundy GR. Monocytes regulate osteoclast-activating factor production by releasing prostaglandins. J Exp Med 1979; 150(2): 338-350. Dostupné z DOI: <http://dx.doi.org/10.1084/jem.150.2.338>. Go to original source...
    8. Salvio G, Gianfelice C, Firmani F et al. Bone metabolism in SARS -⁠ -CoV-2 disease: possible osteoimmunology and gender implications. Clin Rev Bone Mineral Metabol 2020; 18(1-7): 51-57. Dostupné z DOI: <https://doi.org/10.1007/s12018-020-09274-3>. Go to original source...
    9. Obitsu S, Ahmed N, Nishitsuji H et al. Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein. Arch Virol 2009; 154 : 1457-1464. Dostupné z DOI: <https://doi.org/10.1007/s00705-009-0472-z>. Go to original source...
    10. Garnero P, Thompson E, Woodworth T et al. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthr Rheum 2010; 62(1): 33-43. Dostupné z DOI: <http://dx.doi.org/10.1002/art.25053>. Go to original source...
    11. Clift AK, Coupland CA, Keogh RH et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ 2020; 371: m3731. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.m3731>. Go to original source...
    12. Center RC, Nguyen TV, Schneider D et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353(9156): 878-882. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(98)09075-8>. Go to original source...
    13. di Filippo L, Formenti AM, Doga M et al. Radiological Thoracic Vertebral Fractures are Highly Prevalent in COVID-19 and Predict Disease Outcomes. J Clin Endocrinol Metab 2021; 106: e602-e614. Dostupné z DOI: <http://doi:10.1210/clinem/dgaa738>. Go to original source...
    14. Daneshkah A, Agrawal V, Eshein A et al. The possible role of vitamin D in supressing cytokine storm and associated mortality in COVID-19 patients. Dostupné z DOI: <https://doi.org/10.1101/2020.04.08.20058578>.
    15. Kunutsor SK, Apekey TA, Steur M. Vitamin D and risk of future hypertension: meta-analysis of 283,537 participants. Eur J Epidemiol 2013; 28(3): 205-221. Dostupné z DOI: <http://dx.doi.org/10.1007/s10654-013-9790-2>. Go to original source...
    16. Mauss D, Jarczok MN, Hoffmann K et al. Associations of vitamin D levels with type 2 diabetes in older working adults. Int J Med Sci 2015; 12(5): 362-368. Dostupné z DOI: <http://dx.doi.org/10.7150/ijms.10540>. Go to original source...
    17. Yao Y, Zhu L, He L et al. A meta-analysis of the relationship between vitamin D deficiency and obesity. Int J Clin Exp Med 2015; 8(9): 14977-14984.
    18. Herrick KA, Storandt RJ, Afful J et al. Vitamin D status in the United States. Am J Clin Nutr 2019; 110(1): 150-157. Dostupné z DOI: <http://dx.doi.org/10.1093/ajcn/nqz037>. Go to original source...
    19. Colotta F, Jansson B, Bonelli F. Modulation of imflammatory and immune responses by vitamin D. J Autoimmun 2017; 85 : 78-97. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaut.2017.07.007>. Go to original source...
    20. Jain A, Chaurasia R, Sengar NS et al. Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers. Sci Rep 2020; 10(1): 20191. Dostupné z DOI: <https://doi.org/10.1038/s41598-020-77093-z> Go to original source...
    21. Ben-Eltriki M, Hopefl R, Wright JM et al. Association between vitamin D status and risk of developing severe COVID-19 infection: a meta-analysis of observational studies. J Am Coll Nutr 2021; 1-11. Dostupné z DOI: <http://dx.doi.org/10.1080/07315724.2021.1951891>. Go to original source...
    22. Vimaleswaran KS, Forouhi NG, Khunti K. Vitamin D and COVID19. BMJ 2021; 372: n544. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.n544>. Go to original source...
    23. Kirwan R, McCullough D, Butler T et al. Sarcopenia during COVID19 lockdown restrictions: long-term health effects of short-term muscle loss. Geroscience 2020; 42(6): 1547-1578. Dostupné z DOI: <http://dx.doi.org/10.1007/s11357-020-00272-3>. Go to original source...
    24. The International Society for Clinical Densitometry. COVID-19 Statements. Statement March 30, 2020. Dostupné z WWW: <https://iscd.org/knowledge-base/march-30-2020-statement/>.
    25. The American Society for Bone and Mineral Research. Joint Guidance on Osteoporosis Management in the Era of COVID-19 from the ASBMR, AACE, Endocrine Society, ERCTS & NOF. Dostupné z WWW: <https://www.asbmr.org/about/statement-detail/joint-guidance-on -⁠ -osteoporosis-management-covid-19>
    26. Yu W, Tsourdi E, Clarke BL et al. Osteoporosis management in the era of COVID-19. J Bone Mineral Res 2020; 35(6): 1009-1013. Dostupné z DOI: <http://dx.doi.org/10.1002/jbmr.4049>. Go to original source...
    27. Paskins Z, Crawford-Manning F, Bullock L et al. Identifying and managing osteoporosis before and after COVID-19: rise of the remote consultations? Osteoporos Int 2020; 31(9): 1629-1632. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198-020-05465-2>. Go to original source...
    28. Blanch-Rubió J, Soldevila-Domenech N, Tío L et al. Influence of anti-osteoporosis treatments on the incidence of COVID-19 in patients with non-inflammatory rheumatic conditions. Aging 2020; 12(20): 19923-19937. Dostupné z DOI: <http://dx.doi.org/10.18632/aging.104117>. Go to original source...
    29. Tsourdi E, Zillikens MC, Meier C et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS.. J Clin Endocrinol Metab 2021; 106 : 264-281. Dostupné z DOI: <http://doi:10.1210/clinem/dgaa756>. Go to original source...
    30. Hauser B, Alonso N, Riches PL. Review of current real-world experience with teriparatide as treatment of osteoporosis in different patient groups. J Clin Med 2021; 10(7): 1403. Dostupné z DOI: <https://doi.org/10.3390/jcm10071403> Go to original source...
    31. The American Society for Bone and Mineral Research. Joint Guidance on Osteoporosis Management in the Era of COVID-19 from the ASBMR, AACE, Endocrine Society, ERCTS & NOF. Dostupné z WWW: <https://www.asbmr.org/about/statement-detail/joint-guidance-on -⁠ -osteoporosis-management-covid-19>.
    32. Hamspon G, Stone M, Lindsay JR et al. Diagnosis and Management of Osteoporosis during COVID-19: Systematic Review and Practical Guidance. Calcif Tissue Int 2021; 109(4): 351-362. Dostupné z DOI: <https://doi.org/10.1007/s00223-021-00858-9> Go to original source...
    33. Ma Q, Hao ZW, Wang YF. The effect of estrogen in coronavirus disease 2019 Am J Physiol Lung Cell Mol Physiol 2021; 321(1): L219-L227. Dostupné z DOI: <http://dx.doi.org/10.1152/ajplung.00332.2020>. Go to original source...
    34. Kocijan R, Behanova M, Reichardt B et al. Poor adherence to parenteral osteoporosis therapies during COVID-19 pandemic. Arch Osteoporos 2021; 16(1): 46. Dostupné z DOI: <http://dx.doi.org/10.1007/s11657-021-00904-x>. Go to original source...
    35. European Alliance of Associations for Rheumatology. EULAR View-points on SARS-CoV-2 vaccination in patients with RMDs. Dostupné z WWW: <https://www.eular.org/eular_sars_cov_2_vaccination_rmd_patients.cfm>
    36. Siegel CA, Melmed GY, McGovern DPB et al. SARS-Cov-2 vaccination for patients with imflammatory bowel diseases: recommendations from an international consensus meeting. Gut 2021; 70(4): 635-640. Dostupné z DOI: http://dx.doi.org/10.1136/gutjnl-2020-⁠ 324000>. Go to original source...
    37. Benucci M, Infantino M, Marotto D et al. Vaccination against SARS -⁠ -CoV-2 in patients with rheumatic diseases: doubts and perspectives. Clin Experimental Rheumatol 2021; 39(1): 196-202. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.